Table 3.
Association between exposure to benzodiazepine or benzodiazepine related drugs and cancer risk, specified by exposure pattern within the entire follow-up-period, excluding the last year prior to the index date
| Subgroup | Cases | Controls | Crude OR (95% CI) | Adjusted OR* (95% CI) |
|---|---|---|---|---|
| Exposed/unexposed | Exposed/unexposed | |||
| Cumulative amount of all BZRD | ||||
| 1–99 DDD | 21 756/118 067 | 167 226/957 778 | 1.06 (1.04, 1.07) | 1.03 (1.01, 1.05) |
| 100–199 DDD | 3 206/118 067 | 24 378/957 778 | 1.08 (1.04, 1.12) | 1.04 (1.00, 1.08) |
| 200–499 DDD | 3 107/118 067 | 22 159/957 778 | 1.13 (1.08, 1.17) | 1.08 (1.04, 1.13) |
| 500–999 DDD | 1 628/118 067 | 11 722/957 778 | 1.13 (1.08, 1.20) | 1.09 (1.03, 1.15) |
| >1000 DDD | 1 596/118 067 | 11 466/957 778 | 1.13 (1.07, 1.19) | 1.07 (1.01, 1.13) |
| Length of exposure | ||||
| <1 year | 21 839/118 067 | 167 443/957 778 | 1.06 (1.04, 1.08) | 1.03 (1.02, 1.05) |
| 1.0–2.9 years | 6 170/118 067 | 46 052/957 778 | 1.09 (1.06, 1.12) | 1.05 (1.02, 1.08) |
| 3.0–6.9 years | 2 826/118 067 | 20 276/957 778 | 1.13 (1.08, 1.17) | 1.07 (1.03, 1.12) |
| >7 years | 458/118 067 | 3 180/957 778 | 1.19 (1.07, 1.31) | 1.11 (1.01, 1.23) |
| Average amount per day within periods classified as exposed | ||||
| 0.00–0.09 DDD/day | 8 976/118 067 | 69 627/957 778 | 1.05 (1.02, 1.07) | 1.02 (1.00, 1.05) |
| 0.10–0.19 DDD/day | 8 118/118 067 | 62 203/957 778 | 1.06 (1.04, 1.09) | 1.03 (1.01, 1.06) |
| 0.20–0.49 DDD/day | 9 216/118 067 | 68 986/957 778 | 1.08 (1.06, 1.11) | 1.04 (1.02, 1.07) |
| 0.50–0.99 DDD/day | 3 687/118 067 | 26 612/957 778 | 1.12 (1.09, 1.17) | 1.08 (1.04, 1.12) |
| >1.00 DDD/day | 1 296/118 067 | 9 523/957 778 | 1.11 (1.04, 1.17) | 1.04 (0.98, 1.11) |
BZRD, benzodiazepine and benzodiazepine related drugs. Note: All cancer sites are included.
*
Adjusted for use of aspirin, non-aspirin-NSAIDs, 5-α-reductase inhibitors, statins, angiotensin-II antagonists, oral contraceptives and hormone supplements, antidepressants, antipsychotics, diagnoses of inflammatory bowel disease, COPD, diabetes, alcohol abuse and Charlson Comorbidity Index score.